|
|
Article: Strong results for B-MS/Otsuka's Abilify.(Bristol-Myers Squibb Co.)(Otsuka Pharmaceutical Company Ltd.)(Brief article)
- Article from:
- Pharma Marketletter
- Article date:
- March 20, 2006
CopyrightCOPYRIGHT 2006 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
US drug major Bristol-Myers Squibb and Japan's Otsuka Pharmaceutical says that their co-devloped antipsychotic, Abilify (aripiprazole) demonstrated statistically-superior effectiveness to the standard of care in schizophrenia.
Data presented at the 14th European Congress of Psychiatry, held in Nice, France, show that the agent was more effective than the standard drugs olanzapine, quetiapine and risperidone, as measured by the Investigator Assessment Questionnaire total score, based on 10 different factors.
In this study, people with schizophrenia treated with Abilify experienced significantly less weight gain, improved ...